U.S., April 24 -- ClinicalTrials.gov registry received information related to the study (NCT06940674) titled 'Adjunctive Cannabidiol for Recovery From Opioid Study' on April 15.
Brief Summary: The long-term goal of the project is to determine whether cannabidiol (CBD) can reduce craving and relapse in individuals with opioid use disorder (OUD). The first phase of this project was an open cross-over design study in healthy individuals to confirm the safety and pharmacokinetic (PK) effects of CBD (BSPG CBD; Brains Bioceutical). The second phase was a double-blinded randomized controlled trial to determine whether CBD reduces craving and anxiety in individuals with OUD maintained on opioid agonist therapy. This phase 3 trial will determine wh...